Tagrisso 80 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F9KC2
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $96,193
Award facts
- Contract value 100% obligated
- $96,193.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $96,193.44 delivery order to Amerisourcebergen Drug Corp (UEI: KABZK8W6PQT3) on January 7, 2026, for the supply of TAGRISSO 80 MG tablets (30-count packaging). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of January 29, 2026. The work will be performed at Amerisourcebergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under Amerisourcebergen's parent company Cencora, Inc.'s significant Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for supplying pharmaceutical products and medical supplies to support military healthcare programs globally.
Amerisourcebergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems through the Defense Logistics Agency. The company's broader contract portfolio demonstrates extensive capability across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical devices. This delivery order for TAGRISSO—an oncology pharmaceutical used in lung cancer treatment—exemplifies the company's role in supplying essential prescription medications to support Defense Health Agency operations and other government healthcare systems. The competitively awarded nature of this contract and others in the company's federal portfolio reflects Amerisourcebergen's demonstrated capability to meet rigorous federal procurement standards.
Quick answers
Who was awarded contract SPE2DR26F9KC2?
SPE2DR26F9KC2 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26F9KC2 worth?
The government has obligated $96,193 on SPE2DR26F9KC2.
Is contract SPE2DR26F9KC2 an order under another contract?
Yes. SPE2DR26F9KC2 is a delivery order under SPE2DR25D2206, an indefinite delivery contract.
Was contract SPE2DR26F9KC2 competed?
The extent of competition for SPE2DR26F9KC2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award